- Home
- MDCX vs CMMB Comparison
MDCX vs CMMB Comparison
Compare MDCX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | CMMB |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 10.2M |
| IPO Year | 2025 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MDCX | CMMB |
|---|---|---|
| Price | $3.37 | $1.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $225.00 | $15.00 |
| AVG Volume (30 Days) | ★ 2.4M | 125.3K |
| Earning Date | 11-13-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $32.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $1.05 |
| 52 Week High | $4.69 | $3.45 |
Technical Indicators
Market Signals| Indicator | MDCX | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 83.66 | 29.81 |
| Support Level | $0.26 | $1.05 |
| Resistance Level | N/A | $1.89 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | 0.37 | -0.01 |
| Stochastic Oscillator | 70.36 | 30.45 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.